Research: Consider Quality of Life When Evaluating Cancer Drug Studies

October 2, 2018

(UPI) – Researchers have determined the cancer patient’s quality of life needs to be considered when studying the effectiveness of drug trials. Reviewed and quantitatively analyzed were 52 articles reporting on 38 randomized clinical trials involving 13,979 cancer patients across 12 cancer types. According to the findings, published Friday in the Journal of the American Medical Association Internal Medicine, there was no significant association between survival when the disease is not getting worse, or “progression-free survival, and health-related quality of life.

Recommended Reading